Survodutide 6.0 mg significantly reduces liver fat by 84% and body weight by 12.2% in obesity with MASLD
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), represent a significant global health burden, often co-occurring with obesity. Currently, there are limited approved pharmacotherapies specifically for MASLD/MASH, with treatment largely relying on lifestyle modifications. This creates a critical unmet need for effective drug interventions that can address both the underlying metabolic dysfunction and the liver pathology. Survodutide, a novel dual agonist targeting the glucagon receptor and glucagon-like peptide-1 receptor (GLP-1R), is being investigated for its potential to simultaneously improve metabolic parameters and reduce liver fat, offering a promising therapeutic avenue.
Study Design
This phase 3, randomized, double-blind, placebo-controlled SYNCHRONIZE-MASLD trial enrolled 216 adults (n=131 female, n=85 male) with obesity (BMI ≥30 kg m-2 or ≥27 kg m-2 with complications) and at-risk MASLD. Participants were randomized 2:1 to receive once-weekly subcutaneous injections of survodutide 6.0 mg (n=146) or placebo (n=70) for 48 weeks. Co-primary endpoints were the percentage of patients achieving ≥30% reduction in MRI-PDFF-assessed liver fat content (LFC) and the percentage change in body weight, both measured from baseline to week 48.
Results
Survodutide treatment demonstrated statistically and clinically superior reductions in both liver fat content and body weight compared to placebo. Using the efficacy estimand, a remarkable 84.2% of survodutide-treated patients achieved ≥30% reduction in LFC, compared to only 24.3% of placebo-treated patients (P < 0.0001). The treatment regimen estimand showed similar significance, with 68.5% vs 28.6% achieving this endpoint (P < 0.0001).
Key Findings
- Survodutide 6.0 mg significantly reduced liver fat content (LFC) by ≥30% in 84.2% of patients with obesity and MASLD.
- Placebo-treated patients achieved ≥30% LFC reduction in only 24.3% of cases (P < 0.0001).
- Mean body weight change was -12.2% with survodutide vs. -1.0% with placebo (P < 0.0001).
- Gastrointestinal adverse events were the most common with survodutide, generally mild-to-moderate and occurring during dose escalation.
Why It Matters
This phase 3 data positions survodutide as a highly promising therapeutic option for individuals with obesity and MASLD, potentially offering a dual benefit by addressing both conditions simultaneously. The significant reductions in liver fat and body weight observed could fundamentally change the treatment landscape for MASLD, a condition with limited current pharmacotherapy. For peptide users and clinicians, this suggests a future where a single agent could manage both metabolic dysfunction and liver health, potentially reducing the need for multiple medications. While a usable protocol is still pending regulatory approval, these results indicate a strong potential for survodutide to become a cornerstone therapy, offering a more comprehensive approach than existing GLP-1R mono-agonists by leveraging its dual GLP-1R/glucagon receptor agonism.
survodutide
obesity
masld
nash
liver-fat
glp-1-agonist